Healthcare Industry News: hemodialysis
News Release - February 12, 2019
Pursuit Vascular's ClearGuard(R) HD Caps Selected as Top Infection Control Product for 2019MAPLE GROVE, Minn., Feb. 12, 2019 -- (Healthcare Sales & Marketing Network) -- Pursuit Vascular, Inc., manufacturer of ClearGuardŽ HD Antimicrobial Barrier Caps, today announced that Becker's Hospital Review selected ClearGuard HD caps as one of its "100 Infection Control Products to Know" for 2019, marking the third year in a row for the innovative caps to be named to this distinguished list.
"Patient safety and infection control are critical for hospitals and healthcare providers to produce the best possible outcomes for patients and avoid preventable infections and errors," notes Becker's. "The ClearGuard HD Antimicrobial Barrier Cap is clinically shown to significantly reduce catheter-related bloodstream infections in hemodialysis patients using central venous catheters."
The annual listing highlights innovative products designed to "reduce preventable complications, stop the spread of germs and make surgery safer for patients." The list is developed based on nominations and internal research conducted by the Becker's Healthcare editorial team; companies do not pay and cannot pay for inclusion in the list.
The ClearGuard HD cap is the only device available for sale in the U.S. that has been clinically proven to reduce bloodstream infections in hemodialysis patients by ~70%. Bloodstream infection is the leading cause of hospitalizations and the second leading cause of death in hemodialysis patients, with catheters causing the vast majority of these infections.
"We are extremely honored to once again be recognized by Becker's as a top infection control product," said Doug Killion, President and CEO of Pursuit Vascular. "We're passionate about providing cost-effective products that reduce infection and improve the lives of patients."
About Pursuit Vascular
Headquartered in Maple Grove, Minnesota, Pursuit Vascular, Inc., develops innovative products designed to protect patients from life-threatening infections, their associated complications, and death, while reducing healthcare costs worldwide. The company's ClearGuard HD Antimicrobial Barrier Cap is the first and only device available for sale in the US that is proven to reduce central line-associated bloodstream infections in hemodialysis patients. For more information, visit www.pursuitvascular.com.
Source: Pursuit Vascular
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.